MorphoSys (MOR) Competitors

$18.96 0.00 (0.00%)

As of 05/4/2026

MOR vs. ELAN, ARWR, AXSM, PRAX, and ABVX

Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does MorphoSys compare to Elanco Animal Health?

MorphoSys (NASDAQ:MOR) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

: Elanco Animal Health has a consensus target price of $27.90, indicating a potential upside of 21.05%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than MorphoSys.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Elanco Animal Health
1 Sell rating(s)

2 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.77
: MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.
: MorphoSys has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
Elanco Animal Health $4.72B 2.43 -$232M -$0.48 N/A
: Elanco Animal Health has a net margin of -4.92% compared to MorphoSys' net margin of -226.79%. Elanco Animal Health's return on equity of 7.16% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
Elanco Animal Health -4.92% 7.16% 3.53%
: 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: In the previous week, Elanco Animal Health had 8 more articles in the media than MorphoSys. MarketBeat recorded 8 mentions for Elanco Animal Health and 0 mentions for MorphoSys. Elanco Animal Health's average media sentiment score of 0.44 beat MorphoSys' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.
Company Overall Sentiment
MorphoSys Neutral
Elanco Animal Health Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Elanco Animal Health	$4.72B	2.43	-$232M	-$0.48	N/A

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Elanco Animal Health	-4.92%	7.16%	3.53%

Company	Overall Sentiment
MorphoSys	Neutral
Elanco Animal Health	Neutral

Summary

Elanco Animal Health beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Arrowhead Pharmaceuticals?

MorphoSys (NASDAQ:MOR) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

: Arrowhead Pharmaceuticals has a net margin of 18.54% compared to MorphoSys' net margin of -226.79%. Arrowhead Pharmaceuticals' return on equity of 35.64% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
Arrowhead Pharmaceuticals 18.54% 35.64% 13.61%
: MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
: In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than MorphoSys. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 0 mentions for MorphoSys. Arrowhead Pharmaceuticals' average media sentiment score of 0.81 beat MorphoSys' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
MorphoSys Neutral
Arrowhead Pharmaceuticals Positive
: 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Arrowhead Pharmaceuticals has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
Arrowhead Pharmaceuticals $829.45M 12.65 -$1.63M $1.53 48.97
: Arrowhead Pharmaceuticals has a consensus target price of $84.20, indicating a potential upside of 12.37%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than MorphoSys.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Arrowhead Pharmaceuticals
0 Sell rating(s)

3 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.83

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Arrowhead Pharmaceuticals	18.54%	35.64%	13.61%

Company	Overall Sentiment
MorphoSys	Neutral
Arrowhead Pharmaceuticals	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Arrowhead Pharmaceuticals	$829.45M	12.65	-$1.63M	$1.53	48.97

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Arrowhead Pharmaceuticals beats MorphoSys on 17 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Axsome Therapeutics?

MorphoSys (NASDAQ:MOR) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

: Axsome Therapeutics has a net margin of -28.69% compared to MorphoSys' net margin of -226.79%. Axsome Therapeutics' return on equity of -232.61% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
Axsome Therapeutics -28.69% -232.61% -25.84%
: MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.
: In the previous week, Axsome Therapeutics had 44 more articles in the media than MorphoSys. MarketBeat recorded 44 mentions for Axsome Therapeutics and 0 mentions for MorphoSys. Axsome Therapeutics' average media sentiment score of 0.38 beat MorphoSys' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
MorphoSys Neutral
Axsome Therapeutics Neutral
: 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: Axsome Therapeutics has higher revenue and earnings than MorphoSys. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
Axsome Therapeutics $638.50M 17.97 -$183.17M -$3.69 N/A
: Axsome Therapeutics has a consensus target price of $251.89, indicating a potential upside of 12.93%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than MorphoSys.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Axsome Therapeutics
1 Sell rating(s)

1 Hold rating(s)

18 Buy rating(s)

1 Strong Buy rating(s)
2.90

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Axsome Therapeutics	-28.69%	-232.61%	-25.84%

Company	Overall Sentiment
MorphoSys	Neutral
Axsome Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Axsome Therapeutics	$638.50M	17.97	-$183.17M	-$3.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Axsome Therapeutics beats MorphoSys on 13 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

: 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
: Praxis Precision Medicines presently has a consensus target price of $590.78, indicating a potential upside of 77.25%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than MorphoSys.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)

12 Buy rating(s)

5 Strong Buy rating(s)
3.00
MorphoSys
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Praxis Precision Medicines has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Praxis Precision Medicines' return on equity of -58.74% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
Praxis Precision Medicines N/A -58.74% -53.54%
MorphoSys -226.79% -694.31% -22.55%
: In the previous week, Praxis Precision Medicines had 7 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 0 mentions for MorphoSys. Praxis Precision Medicines' average media sentiment score of 1.10 beat MorphoSys' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Company Overall Sentiment
Praxis Precision Medicines Positive
MorphoSys Neutral
: MorphoSys has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Praxis Precision Medicines N/A N/A -$303.27M -$13.46 N/A
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.00
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-58.74%	-53.54%
MorphoSys	-226.79%	-694.31%	-22.55%

Company	Overall Sentiment
Praxis Precision Medicines	Positive
MorphoSys	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.46	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summary

Praxis Precision Medicines beats MorphoSys on 11 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Abivax?

Abivax (NASDAQ:ABVX) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

: 47.9% of Abivax shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
: Abivax presently has a consensus target price of $137.15, indicating a potential upside of 10.80%. Given Abivax's stronger consensus rating and higher probable upside, equities research analysts clearly believe Abivax is more favorable than MorphoSys.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
0 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.93
MorphoSys
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Abivax has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Abivax's return on equity of -146.43% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
Abivax N/A -146.43% -88.69%
MorphoSys -226.79% -694.31% -22.55%
: In the previous week, Abivax had 7 more articles in the media than MorphoSys. MarketBeat recorded 7 mentions for Abivax and 0 mentions for MorphoSys. Abivax's average media sentiment score of 1.45 beat MorphoSys' score of 0.00 indicating that Abivax is being referred to more favorably in the media.
Company Overall Sentiment
Abivax Positive
MorphoSys Neutral
: MorphoSys has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abivax N/A N/A -$380.27M -$5.37 N/A
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
MorphoSys	-226.79%	-694.31%	-22.55%

Company	Overall Sentiment
Abivax	Positive
MorphoSys	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summary

Abivax beats MorphoSys on 9 of the 16 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOR vs. The Competition

Export

Metric	MorphoSys	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.86B	$892.88M	$6.25B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	-5.45	1.72	29.04	28.47
Price / Sales	11.99	120.50	476.61	60.94
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	54.17	7.60	9.67	6.67
Net Income	-$205.35M	-$4.80M	$3.55B	$332.53M
7 Day Performance	N/A	-0.02%	1.70%	2.01%
1 Month Performance	N/A	5.52%	5.62%	9.20%
1 Year Performance	N/A	30.99%	34.42%	39.59%

MorphoSys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ELAN Elanco Animal Health	3.2796 of 5 stars	$21.81 -1.5%	$27.90 +27.9%	N/A	$10.85B	$4.72B	N/A	9,400	Upcoming Earnings
ARWR Arrowhead Pharmaceuticals	2.6361 of 5 stars	$70.53 +0.6%	$83.78 +18.8%	N/A	$9.88B	$829.45M	46.10	400	News Coverage Upcoming Earnings
AXSM Axsome Therapeutics	3.17 of 5 stars	$183.95 -0.6%	$218.06 +18.5%	N/A	$9.41B	$638.50M	N/A	380	Trending News Earnings Report Analyst Forecast
PRAX Praxis Precision Medicines	3.3965 of 5 stars	$323.19 +0.4%	$590.78 +82.8%	N/A	$9.00B	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Competitors

MOR vs. ELAN, ARWR, AXSM, PRAX, and ABVX

How does MorphoSys compare to Elanco Animal Health?

Summary

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Summary

How does MorphoSys compare to Axsome Therapeutics?

Summary

How does MorphoSys compare to Praxis Precision Medicines?

Summary

How does MorphoSys compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MorphoSys (MOR) Competitors

MOR vs. ELAN, ARWR, AXSM, PRAX, and ABVX

How does MorphoSys compare to Elanco Animal Health?

Summary

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Summary

How does MorphoSys compare to Axsome Therapeutics?

Summary

How does MorphoSys compare to Praxis Precision Medicines?

Summary

How does MorphoSys compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools